Cyclin-dependent kinase 5 acts as a promising biomarker in clear cell Renal Cell Carcinoma

BackgroundThis research provides the first evidence of CDK5 in ccRCC prognosis and correlation with different p21 expression in overall survival (OS) analysis.MethodsThe data from both of The Cancer Genome Atlas (TCGA) and Gene Expression of Normal and Tumor Tissue (GENT) were analyzed for determining the expression of CDK5 in kidney cancer. Tissue microarray that made by using 150 ccRCC samples was used in immunohistochemistry (IHC) analysis. A validation of OS cohort was extracted from Oncomine database.ResultsThe CDK5 expression was significantly lower in cancer tissue compared with normal in TCGA (p < 0.0001), GENT database also showed a relative low expression in kidney cancer. Among 150 ccRCC patients, low CDK5 was detected in 83 cases (55.3%), low p21 in 97 cases (64.7%). CDK5 was associated with the advanced TNM stage (p = 0.042), and Fuhrman grade (p = 0.035). Patients with lower CDK5 might be more likely to be aggressive status. According to the combination analysis of CDK5 and p21, patients in CDK5 low/p21 low group showed poorer survival rate, and no significant survival difference was observed in other groups. In the Cox multivariate analysis, the co-expression of CDK5 low/p21 low was identified as an independent prognostic factor in ccRCC patients.ConclusionsTogether, our findings provided the first evidence that CDK5 was acting as a promising biomarker in ccRCC patients, and co-expression of CDK5 and p21 is an independent prognostic for overall survival. IHC analysis of CDK5 and p21 on cancer tissues after surgery may help to evaluate and predict the outcome of ccRCC patients.

[1]  E. Nakakura,et al.  Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. , 2006, Cancer research.

[2]  F. Gao,et al.  The functions and properties of cullin-5, a potential therapeutic target for cancers. , 2020, American journal of translational research.

[3]  Li-Huei Tsai,et al.  A decade of CDK5 , 2001, Nature Reviews Molecular Cell Biology.

[4]  J. Hsieh,et al.  Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser⁷²⁷ on STAT3 in prostate cancer cells. , 2013, American journal of physiology. Endocrinology and metabolism.

[5]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[6]  J. Hsieh,et al.  Cdk5 Directly Targets Nuclear p21CIP1 and Promotes Cancer Cell Growth. , 2016, Cancer research.

[7]  G. Feldmann,et al.  Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. , 2010, Cancer research.

[8]  J. Bibb,et al.  The role of Cdk5 in neuroendocrine thyroid cancer. , 2013, Cancer cell.

[9]  S. Hisanaga,et al.  Regulation and role of cyclin‐dependent kinase activity in neuronal survival and death , 2010, Journal of neurochemistry.

[10]  H. Moch,et al.  Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. , 2016, European urology.

[11]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[12]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[13]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[14]  I. A. Wani,et al.  Recent Advances and Future Prospects , 2019 .

[15]  Jiwei Huang,et al.  LSD1 inhibition suppresses the growth of clear cell renal cell carcinoma via upregulating P21 signaling , 2018, Acta pharmaceutica Sinica. B.

[16]  F. Bray,et al.  Epidemiology of Renal Cell Carcinoma. , 2019, European urology.

[17]  Anindya Dutta,et al.  p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.

[18]  S. Zahler,et al.  Twice switched at birth: cell cycle-independent roles of the "neuron-specific" cyclin-dependent kinase 5 (Cdk5) in non-neuronal cells. , 2011, Cellular signalling.

[19]  Claire D. McWhite,et al.  Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway , 2012, Molecular biology of the cell.

[20]  L. Tsai,et al.  A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease , 2004, Current Opinion in Neurobiology.

[21]  S. Zahler,et al.  Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1α: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma , 2016, Oncotarget.

[22]  S. Zahler,et al.  Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach. , 2014, Journal of hepatology.

[23]  Han Yong Choi,et al.  The epidemiology of renal cell carcinoma. , 2011, European urology.

[24]  Yao Lin,et al.  Low Expression of CDK5 and p27 Are Associated with Poor Prognosis in Patients with Gastric Cancer , 2016, Journal of Cancer.

[25]  H. Pandha,et al.  First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials , 2016, Anti-cancer drugs.

[26]  L. Tsai,et al.  Cyclin-dependent kinases in brain development and disease. , 2011, Annual review of cell and developmental biology.

[27]  Shudong Wang,et al.  CDK5 in oncology: recent advances and future prospects. , 2017, Future medicinal chemistry.